175 related articles for article (PubMed ID: 31140730)
1. Integrative analysis from multi-centre studies identifies a function-derived personalized multi-gene signature of outcome in colorectal cancer.
Sun J; Zhao H; Lin S; Bao S; Zhang Y; Su J; Zhou M
J Cell Mol Med; 2019 Aug; 23(8):5270-5281. PubMed ID: 31140730
[TBL] [Abstract][Full Text] [Related]
2. A prognostic index based on an eleven gene signature to predict systemic recurrences in colorectal cancer.
Kim SK; Kim SY; Kim CW; Roh SA; Ha YJ; Lee JL; Heo H; Cho DH; Lee JS; Kim YS; Kim JC
Exp Mol Med; 2019 Oct; 51(10):1-12. PubMed ID: 31578316
[TBL] [Abstract][Full Text] [Related]
3. Development of a 15-gene signature for predicting prognosis in advanced colorectal cancer.
Wang X; Li T
Bioengineered; 2020 Dec; 11(1):165-174. PubMed ID: 32036725
[TBL] [Abstract][Full Text] [Related]
4. CRC-113 gene expression signature for predicting prognosis in patients with colorectal cancer.
Nguyen MN; Choi TG; Nguyen DT; Kim JH; Jo YH; Shahid M; Akter S; Aryal SN; Yoo JY; Ahn YJ; Cho KM; Lee JS; Choe W; Kang I; Ha J; Kim SS
Oncotarget; 2015 Oct; 6(31):31674-92. PubMed ID: 26397224
[TBL] [Abstract][Full Text] [Related]
5. Discovery of a novel six-long non-coding RNA signature predicting survival of colorectal cancer patients.
Fan Q; Liu B
J Cell Biochem; 2018 Apr; 119(4):3574-3585. PubMed ID: 29227531
[TBL] [Abstract][Full Text] [Related]
6. Identification of a five-gene signature with prognostic value in colorectal cancer.
Sun G; Li Y; Peng Y; Lu D; Zhang F; Cui X; Zhang Q; Li Z
J Cell Physiol; 2019 Apr; 234(4):3829-3836. PubMed ID: 30132881
[TBL] [Abstract][Full Text] [Related]
7. Construction and optimization of gene expression signatures for prediction of survival in two-arm clinical trials.
Theilhaber J; Chiron M; Dreymann J; Bergstrom D; Pollard J
BMC Bioinformatics; 2020 Jul; 21(1):333. PubMed ID: 32711453
[TBL] [Abstract][Full Text] [Related]
8. Identification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer.
Gao S; Tibiche C; Zou J; Zaman N; Trifiro M; O'Connor-McCourt M; Wang E
JAMA Oncol; 2016 Jan; 2(1):37-45. PubMed ID: 26502222
[TBL] [Abstract][Full Text] [Related]
9. Gene pair based prognostic signature for colorectal colon cancer.
Shu P; Wu J; Tong Y; Xu C; Zhang X
Medicine (Baltimore); 2018 Oct; 97(42):e12788. PubMed ID: 30334969
[TBL] [Abstract][Full Text] [Related]
10. A TMEFF2-regulated cell cycle derived gene signature is prognostic of recurrence risk in prostate cancer.
Georgescu C; Corbin JM; Thibivilliers S; Webb ZD; Zhao YD; Koster J; Fung KM; Asch AS; Wren JD; Ruiz-Echevarría MJ
BMC Cancer; 2019 May; 19(1):423. PubMed ID: 31060542
[TBL] [Abstract][Full Text] [Related]
11. A network-based predictive gene-expression signature for adjuvant chemotherapy benefit in stage II colorectal cancer.
Cao B; Luo L; Feng L; Ma S; Chen T; Ren Y; Zha X; Cheng S; Zhang K; Chen C
BMC Cancer; 2017 Dec; 17(1):844. PubMed ID: 29237416
[TBL] [Abstract][Full Text] [Related]
12. Identification and Clinical Validation of a Novel 4 Gene-Signature with Prognostic Utility in Colorectal Cancer.
Ahluwalia P; Mondal AK; Bloomer C; Fulzele S; Jones K; Ananth S; Gahlay GK; Heneidi S; Rojiani AM; Kota V; Kolhe R
Int J Mol Sci; 2019 Aug; 20(15):. PubMed ID: 31387239
[TBL] [Abstract][Full Text] [Related]
13. A Stepwise Integrated Approach to Personalized Risk Predictions in Stage III Colorectal Cancer.
Salvucci M; Würstle ML; Morgan C; Curry S; Cremona M; Lindner AU; Bacon O; Resler AJ; Murphy ÁC; O'Byrne R; Flanagan L; Dasgupta S; Rice N; Pilati C; Zink E; Schöller LM; Toomey S; Lawler M; Johnston PG; Wilson R; Camilleri-Broët S; Salto-Tellez M; McNamara DA; Kay EW; Laurent-Puig P; Van Schaeybroeck S; Hennessy BT; Longley DB; Rehm M; Prehn JH
Clin Cancer Res; 2017 Mar; 23(5):1200-1212. PubMed ID: 27649552
[No Abstract] [Full Text] [Related]
14. Identification of Genes Related to Clinicopathological Characteristics and Prognosis of Patients with Colorectal Cancer.
Gao X; Yang J
DNA Cell Biol; 2020 Apr; 39(4):690-699. PubMed ID: 32027181
[TBL] [Abstract][Full Text] [Related]
15. Mechanistically derived patient-level framework for precision medicine identifies a personalized immune prognostic signature in high-grade serous ovarian cancer.
Zhao H; Gu S; Bao S; Yan C; Zhang Z; Hou P; Zhou M; Sun J
Brief Bioinform; 2021 May; 22(3):. PubMed ID: 32436954
[TBL] [Abstract][Full Text] [Related]
16. Commonality and differences of methylation signatures in the plasma of patients with pancreatic cancer and colorectal cancer.
Melson J; Li Y; Cassinotti E; Melnikov A; Boni L; Ai J; Greenspan M; Mobarhan S; Levenson V; Deng Y
Int J Cancer; 2014 Jun; 134(11):2656-62. PubMed ID: 24288256
[TBL] [Abstract][Full Text] [Related]
17. A molecular signature for the prediction of recurrence in colorectal cancer.
Wang L; Shen X; Wang Z; Xiao X; Wei P; Wang Q; Ren F; Wang Y; Liu Z; Sheng W; Huang W; Zhou X; Du X
Mol Cancer; 2015 Feb; 14(1):22. PubMed ID: 25645394
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of Osteopontin (SPP1) in colorectal carcinoma requires a personalized molecular approach.
Assidi M; Gomaa W; Jafri M; Hanbazazh M; Al-Ahwal M; Pushparaj P; Al-Harbi A; Al-Qahtani M; Buhmeida A; Al-Maghrabi J
Tumour Biol; 2019 Sep; 41(9):1010428319863627. PubMed ID: 31500540
[TBL] [Abstract][Full Text] [Related]
19. Survival marker genes of colorectal cancer derived from consistent transcriptomic profiling.
Martinez-Romero J; Bueno-Fortes S; Martín-Merino M; Ramirez de Molina A; De Las Rivas J
BMC Genomics; 2018 Dec; 19(Suppl 8):857. PubMed ID: 30537927
[TBL] [Abstract][Full Text] [Related]
20. Gene expression profiling-derived immunohistochemistry signature with high prognostic value in colorectal carcinoma.
Chang W; Gao X; Han Y; Du Y; Liu Q; Wang L; Tan X; Zhang Q; Liu Y; Zhu Y; Yu Y; Fan X; Zhang H; Zhou W; Wang J; Fu C; Cao G
Gut; 2014 Sep; 63(9):1457-67. PubMed ID: 24173294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
